Abstract
Introduction The PROMISE study was launched in 2018 to assess and document the implementation of changes to an existing HIV Care Coordination Program (CCP) designed to address persistent disparities in care and treatment engagement among persons with HIV in New York City. We evaluated provider endorsement of features of the CCP to identify opportunities for improvement.
Methods We used a discrete choice experiment (DCE) to measure provider endorsement of four CCP attributes, including: a) how CCP helps with medication adherence, b) how CCP helps with primary care appointments, c) how CCP helps with issues other than primary care, and d) where CCP visits take place (visit location). Each attribute had three to four levels. Our primary outcomes were relative importance and part-worth utilities, measures of preference for the levels of the four CCP program attributes.
Results Visit location (28.6%) had the highest relative importance, followed by how staff help with ART adherence (24.3%), how staff help with issues other than primary care (24.2%), and how staff help with primary care appointments (22.9%). Within each of the above attributes, respectively, the levels with the highest part-worth utilities were home visits 60 minutes from the program or agency (19.9 utiles, 95% CI 10.7-29.0), directly observed therapy (26.1 utiles, 95% CI 19.1-33.1), help with non-HIV specialty medical care (26.5 utiles, 95% CI 21.5-31.6), and reminding clients about and accompanying them to primary care appointments (20.8 utiles, 95% CI 15.6-26.0).
Conclusions Ongoing CCP refinements should account for how best to support and evaluate the intensive CCP components endorsed by providers in this study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH117793.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols and materials were reviewed and approved by the NYC Health Department institutional review board (IRB), which served as the IRB of record for the PROMISE study. All participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is not publicly available.
